May 23, 2019 09:34 AM EDTUpdated 03:05 PM
Pharma

In a change of plans, Nek­tar spins out its opi­oid in­to a new biotech sub­sidiary as FDA PDU­FA date looms

John Carroll

Editor & Founder

Nek­tar Ther­a­peu­tics is spin­ning off a new biotech com­pa­ny and gift­ing it with their late-stage pain drug NK­TR-181 just three months ahead of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

Pfiz­er hires No­var­tis on­col­o­gy ex­ec to steer its can­cer am­bi­tions

Bris­tol My­ers prunes pipeline amid new round of cost cuts

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

Up­dat­ed: Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

A service from the Financial Times